JP2002542270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542270A5 JP2002542270A5 JP2000613391A JP2000613391A JP2002542270A5 JP 2002542270 A5 JP2002542270 A5 JP 2002542270A5 JP 2000613391 A JP2000613391 A JP 2000613391A JP 2000613391 A JP2000613391 A JP 2000613391A JP 2002542270 A5 JP2002542270 A5 JP 2002542270A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polypeptide
- composition according
- gene
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 9
- 231100000457 cardiotoxic Toxicity 0.000 description 6
- 230000001451 cardiotoxic effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 108050003475 Neuregulin Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- ZOXZWYWOECCBSH-UHFFFAOYSA-N 4 Methyl N-ethylcathinone Chemical group CCNC(C)C(=O)C1=CC=C(C)C=C1 ZOXZWYWOECCBSH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 2
- 102400000057 Neuregulin-2 Human genes 0.000 description 2
- 101800000675 Neuregulin-2 Proteins 0.000 description 2
- 102400000054 Neuregulin-3 Human genes 0.000 description 2
- 101800000673 Neuregulin-3 Proteins 0.000 description 2
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000055650 human NRG1 Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/298,121 | 1999-04-23 | ||
| US09/298,121 US6635249B1 (en) | 1999-04-23 | 1999-04-23 | Methods for treating congestive heart failure |
| PCT/US2000/010664 WO2000064400A2 (en) | 1999-04-23 | 2000-04-20 | Methods for treating congestive heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011116364A Division JP2011157402A (ja) | 1999-04-23 | 2011-05-24 | うっ血性心不全を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542270A JP2002542270A (ja) | 2002-12-10 |
| JP2002542270A5 true JP2002542270A5 (https=) | 2007-06-28 |
Family
ID=23149139
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000613391A Withdrawn JP2002542270A (ja) | 1999-04-23 | 2000-04-20 | うっ血性心不全を処置するための方法 |
| JP2011116364A Pending JP2011157402A (ja) | 1999-04-23 | 2011-05-24 | うっ血性心不全を処置するための方法 |
| JP2013078262A Expired - Lifetime JP6134190B2 (ja) | 1999-04-23 | 2013-04-04 | うっ血性心不全を処置するための方法 |
| JP2014226670A Pending JP2015034174A (ja) | 1999-04-23 | 2014-11-07 | うっ血性心不全を処置するための方法 |
| JP2017010999A Pending JP2017071649A (ja) | 1999-04-23 | 2017-01-25 | うっ血性心不全を処置するための方法 |
| JP2018023316A Pending JP2018083850A (ja) | 1999-04-23 | 2018-02-13 | うっ血性心不全を処置するための方法 |
| JP2019084077A Pending JP2019142939A (ja) | 1999-04-23 | 2019-04-25 | うっ血性心不全を処置するための方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011116364A Pending JP2011157402A (ja) | 1999-04-23 | 2011-05-24 | うっ血性心不全を処置するための方法 |
| JP2013078262A Expired - Lifetime JP6134190B2 (ja) | 1999-04-23 | 2013-04-04 | うっ血性心不全を処置するための方法 |
| JP2014226670A Pending JP2015034174A (ja) | 1999-04-23 | 2014-11-07 | うっ血性心不全を処置するための方法 |
| JP2017010999A Pending JP2017071649A (ja) | 1999-04-23 | 2017-01-25 | うっ血性心不全を処置するための方法 |
| JP2018023316A Pending JP2018083850A (ja) | 1999-04-23 | 2018-02-13 | うっ血性心不全を処置するための方法 |
| JP2019084077A Pending JP2019142939A (ja) | 1999-04-23 | 2019-04-25 | うっ血性心不全を処置するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US6635249B1 (https=) |
| EP (3) | EP2319529A1 (https=) |
| JP (7) | JP2002542270A (https=) |
| KR (1) | KR20020016773A (https=) |
| AU (1) | AU777300B2 (https=) |
| CA (1) | CA2368357C (https=) |
| WO (1) | WO2000064400A2 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135456B1 (en) * | 1991-04-10 | 2006-11-14 | Acorda Therapeutics, Inc. | Glial mitogenic factors, their preparation and use |
| US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US7037888B1 (en) * | 1992-04-03 | 2006-05-02 | Acorda Therapeutics, Inc. | Methods for treating muscle diseases and disorders |
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| IL153052A0 (en) * | 2000-05-23 | 2003-06-24 | Cenes Pharmaceuticals Inc | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| WO2002042431A2 (en) * | 2000-11-22 | 2002-05-30 | Gwathmey, Inc. | Isolation procedure and optimized media solution to enhance long-term survival of cells |
| US20060034832A1 (en) | 2002-04-26 | 2006-02-16 | Haruhide Kimura | Cell death inhibitor |
| WO2003099320A1 (en) * | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| US8293710B2 (en) * | 2005-01-03 | 2012-10-23 | Blue Blood Biotech Corp. | Method for treating wounds using an EGF-like domain of thrombomodulin |
| US7776817B2 (en) | 2005-09-02 | 2010-08-17 | Morehouse School Of Medicine | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| JP5738516B2 (ja) | 2005-12-30 | 2015-06-24 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | 心機能改善のためのニューレグリンの徐放 |
| AU2013203483B2 (en) * | 2005-12-30 | 2015-11-05 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Extended release of neuregulin for improved cardiac function |
| US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
| CN101743474B (zh) * | 2007-05-10 | 2015-06-03 | 阿索尔达治疗公司 | 检测心脏损伤的方法 |
| US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| US20090291893A1 (en) * | 2008-05-23 | 2009-11-26 | Morehouse School Of Medicine | Compositions for the prevention and treatment of neuroinjury and methods of use thereof |
| CN102159236A (zh) * | 2008-07-17 | 2011-08-17 | 阿索尔达治疗公司 | 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 |
| EP2328606B1 (en) | 2008-08-15 | 2016-10-05 | Acorda Therapeutics, Inc. | Compositions and methods for treatment during non-acute periods following cns neurological injury |
| EP2346526A2 (en) | 2008-09-22 | 2011-07-27 | Massachusetts Institute of Technology | Compositions of and methods of using ligand dimers |
| JP2012509908A (ja) * | 2008-11-28 | 2012-04-26 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリン及び心臓幹細胞 |
| JP5743898B2 (ja) | 2008-11-28 | 2015-07-01 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリンペプチド及びその使用 |
| CA2763161A1 (en) * | 2009-05-29 | 2010-12-02 | Xoma Technology Ltd. | Cardiovascular related uses of il-1.beta. antibodies and binding fragments thereof |
| EP3087998B1 (en) | 2009-06-09 | 2019-09-04 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin based methods for treating heart failure |
| CN102470161A (zh) * | 2009-06-09 | 2012-05-23 | 上海泽生科技开发有限公司 | 神经调节蛋白用于治疗心力衰竭的有效剂量 |
| WO2011011388A2 (en) * | 2009-07-22 | 2011-01-27 | Children's Medical Center Corporation | Neuregulin induced regeneraton of heart muscle muscle |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| US9029328B2 (en) | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| ES2604012T3 (es) | 2012-07-04 | 2017-03-02 | F. Hoffmann-La Roche Ag | Conjugados de antígeno-anticuerpo unidos covalentemente |
| US10894815B2 (en) | 2012-10-08 | 2021-01-19 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Compositions and methods for treating heart failure in diabetic patients |
| EP2964249A1 (en) | 2013-03-06 | 2016-01-13 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure |
| RU2015154737A (ru) | 2013-05-22 | 2017-06-27 | Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности |
| CA2933384A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| KR20170026362A (ko) | 2014-06-26 | 2017-03-08 | 에프. 호프만-라 로슈 아게 | 항-ｂｒｄｕ 항체 및 사용 방법 |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| US10017574B2 (en) | 2015-05-07 | 2018-07-10 | Yeda Research And Development Co. Ltd. | Methods, kits and devices for promoting cardiac regeneration |
| PE20210111A1 (es) | 2018-04-11 | 2021-01-19 | Salubris Biotherapeutics Inc | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso |
| CN111407881A (zh) | 2019-01-07 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| AU2020348436A1 (en) | 2019-09-16 | 2022-04-07 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Recombinant human neuregulin derivatives and use thereof |
| CN113289002A (zh) | 2020-02-24 | 2021-08-24 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 |
| TW202306975A (zh) | 2021-06-10 | 2023-02-16 | 美商安進公司 | 對ｅｒｂｂ４而非ｅｒｂｂ３具有改善的選擇性的工程化ｎｒｇ－１變體 |
| KR20240102971A (ko) | 2021-11-16 | 2024-07-03 | 제넨테크, 인크. | 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물 |
| WO2023178086A1 (en) | 2022-03-15 | 2023-09-21 | Salubris Biotherapeutics, Inc. | Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein |
| WO2025245112A1 (en) | 2024-05-21 | 2025-11-27 | Salubris Biotherapeutics, Inc. | Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1989001489A1 (en) | 1987-08-10 | 1989-02-23 | Commonwealth Scientific And Industrial Research Or | Control of angiogenesis and compositions and methods therefor |
| GB9107566D0 (en) | 1991-04-10 | 1991-05-29 | Ludwig Inst Cancer Res | Glial mitogenic factors,their preparation and use |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US7037888B1 (en) | 1992-04-03 | 2006-05-02 | Acorda Therapeutics, Inc. | Methods for treating muscle diseases and disorders |
| US6087323A (en) | 1992-04-03 | 2000-07-11 | Cambridge Neuroscience, Inc. | Use of neuregulins as modulators of cellular communication |
| FI943071L (fi) | 1993-06-24 | 1994-12-25 | Takeda Chemical Industries Ltd | Anti-endoteliiniainetta pysyvästi vapauttava valmiste |
| US5770567A (en) | 1994-11-14 | 1998-06-23 | Genentech, Inc. | Sensory and motor neuron derived factor (SMDF) |
| JP3342873B2 (ja) | 1995-03-10 | 2002-11-11 | ジェネンテク・インコーポレイテッド | ｇａｓ６による受容体活性化 |
| US6750196B1 (en) | 1995-03-27 | 2004-06-15 | Acorda Therapeutics | Methods of treating disorders of the eye |
| US5714385A (en) | 1995-05-10 | 1998-02-03 | Genentech, Inc. | Media for culturing schwann cells |
| US5721139A (en) | 1995-05-10 | 1998-02-24 | Genentech, Inc. | Isolating and culturing schwann cells |
| US6033660A (en) | 1995-05-10 | 2000-03-07 | Genentech, Inc. | Method of treating a nervous system injury with cultured schwann cells |
| US5919449A (en) * | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| CA2257839C (en) | 1996-07-12 | 2012-10-23 | Genentech, Inc. | Gamma-heregulin |
| WO1998002540A1 (en) * | 1996-07-12 | 1998-01-22 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| UA75316C2 (uk) * | 1996-10-16 | 2006-04-17 | Займодженетікс, Інк. | Гомологи з фактором росту фібробласта |
| US6593290B1 (en) | 1996-11-01 | 2003-07-15 | Genentech, Inc. | Treatment of inner ear hair cells |
| US6156728A (en) | 1996-11-01 | 2000-12-05 | Genentech, Inc. | Treatment of inner ear hair cells |
| WO1998035036A1 (en) | 1997-02-10 | 1998-08-13 | Genentech, Inc. | Heregulin variants |
| US6136558A (en) | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
| AU7727298A (en) | 1997-06-06 | 1998-12-21 | Regents Of The University Of Michigan, The | Neuregulin response element and uses therefor |
| US6121415A (en) | 1997-07-09 | 2000-09-19 | Genentech, Inc. | ErbB4 receptor-specific neuregolin related ligands and uses therefor |
| CA2296704C (en) * | 1997-07-14 | 2010-10-19 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
| JP2001519400A (ja) * | 1997-10-14 | 2001-10-23 | ケンブリッジ ニューロサイエンス インク． | ニューレグリン使用を含む治療法 |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6446242B1 (en) | 1999-04-02 | 2002-09-03 | Actel Corporation | Method and apparatus for storing a validation number in a field-programmable gate array |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| US7776817B2 (en) | 2005-09-02 | 2010-08-17 | Morehouse School Of Medicine | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration |
| WO2012021818A2 (en) | 2010-08-13 | 2012-02-16 | Georgetown University | Ggf2 and methods of use |
-
1999
- 1999-04-23 US US09/298,121 patent/US6635249B1/en not_active Expired - Lifetime
-
2000
- 2000-04-20 EP EP10180490A patent/EP2319529A1/en not_active Withdrawn
- 2000-04-20 EP EP00931938A patent/EP1180040A4/en not_active Ceased
- 2000-04-20 EP EP16156504.9A patent/EP3087997B1/en not_active Expired - Lifetime
- 2000-04-20 CA CA2368357A patent/CA2368357C/en not_active Expired - Lifetime
- 2000-04-20 AU AU49744/00A patent/AU777300B2/en not_active Expired
- 2000-04-20 WO PCT/US2000/010664 patent/WO2000064400A2/en not_active Ceased
- 2000-04-20 JP JP2000613391A patent/JP2002542270A/ja not_active Withdrawn
- 2000-04-20 KR KR1020017013409A patent/KR20020016773A/ko not_active Withdrawn
-
2003
- 2003-08-22 US US10/646,268 patent/US7662772B2/en not_active Expired - Lifetime
-
2009
- 2009-12-29 US US12/655,361 patent/US8076283B2/en not_active Expired - Fee Related
-
2011
- 2011-05-24 JP JP2011116364A patent/JP2011157402A/ja active Pending
- 2011-11-09 US US13/292,193 patent/US8394761B2/en not_active Expired - Fee Related
-
2012
- 2012-10-19 US US13/656,179 patent/US20130040879A1/en not_active Abandoned
-
2013
- 2013-04-04 JP JP2013078262A patent/JP6134190B2/ja not_active Expired - Lifetime
-
2014
- 2014-11-07 JP JP2014226670A patent/JP2015034174A/ja active Pending
-
2015
- 2015-09-03 US US14/844,475 patent/US10232016B2/en not_active Expired - Fee Related
-
2017
- 2017-01-25 JP JP2017010999A patent/JP2017071649A/ja active Pending
-
2018
- 2018-02-13 JP JP2018023316A patent/JP2018083850A/ja active Pending
-
2019
- 2019-04-25 JP JP2019084077A patent/JP2019142939A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002542270A5 (https=) | ||
| CA2368357A1 (en) | Methods for treating congestive heart failure | |
| WO2003044172B1 (en) | Composition comprising and method of using angiopoietin-like protein 3 angptl3 | |
| Lopez et al. | Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia | |
| RU2311921C2 (ru) | Лекарственные средства для лечения ишемических заболеваний | |
| CORDONNIER et al. | Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis | |
| AU729463B2 (en) | Treatment of cardiomyopathy | |
| JP3473623B2 (ja) | うっ血性心不全を治療するための、成長ホルモンとインスリン様成長因子との組み合わせ | |
| CA1341281C (en) | Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen | |
| US5965523A (en) | Method for enhancing transplanted tissue using scatter factor | |
| EA001616B1 (ru) | Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре | |
| JP2014094951A (ja) | 心血管疾患を処置するためのニューレギュリン法および組成物 | |
| CA2235372A1 (en) | Method for treating ischemic tissue | |
| JPH01500199A (ja) | 創傷の治癒および骨の再生 | |
| US7261881B1 (en) | Modulation of angiogenesis and wound healing | |
| Miyazaki et al. | Reversible left ventricular dysfunction" takotsubo" cardiomyopathy associated with hyperthyroidism | |
| RU2004137823A (ru) | Терапевтическое средство против гиперкальциемического криза | |
| EA019099B1 (ru) | Способ направленной доставки трансгена в миокард пациента с ишемией миокарда | |
| EP1001768A1 (en) | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor | |
| Wang et al. | Effects of sildenafil and/or muscle derived stem cells on myocardial infarction | |
| Dean et al. | Cellular distribution of 125I-endothelin-1 binding in rat kidney following in vivo labeling | |
| Kwaan et al. | Localization of fibrinolytic activity in myocardial infarcts in rats | |
| JP2026507871A (ja) | アネキシンａ１投与レジメン | |
| CN1222310C (zh) | 肝实质细胞增殖因子药用制剂 | |
| JP2002535282A5 (https=) |